DEFA14A: Eliem Therapeutics to Acquire Tenet Medicines, Bolstering Autoimmune Pipeline with $120 Million Private Placement

Eliem Therapeutics is set to acquire Tenet Medicines, enhancing its autoimmune disease pipeline with a concurrent $120 million private placement to advance clinical-stage program TNT119.

Summary

• Eliem Therapeutics will acquire Tenet Medicines in an all-stock transaction, focusing on advancing TNT119, an anti-CD19 antibody for autoimmune diseases.
• A concurrent $120 million private placement with life science investors supports the acquisition.
• The combined company is expected to have approximately $210 million in cash, funding operations into 2027.
• TNT119 is planned for Phase 2 clinical trials in systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) in the second half of 2024.
• Tenet stockholders are expected to own approximately 15% of the combined company, while Eliem stockholders will own approximately 85%, before the private placement.
• Stephen Thomas, Tenet's CEO, will become interim CEO of the combined company, and William Bonificio will be interim Chief Business Officer.
• The board will consist of seven members, including existing Eliem board members, Stephen Thomas, and a Tenet designee.
• The acquisition and private placement are expected to close in mid-2024, pending Eliem stockholder approval and customary conditions.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the acquisition and private placement, promising clinical data, and a clear strategic direction. The management's confidence and the support from leading life sciences investors contribute to the high sentiment score.

Positives

• The acquisition provides Eliem with a clinical-stage asset, TNT119, targeting a broad range of autoimmune diseases.
• The $120 million private placement extends the cash runway into 2027, supporting key clinical milestones.
• TNT119 has shown promising early clinical data in membranous nephropathy.
• The combined company will have an experienced leadership team with expertise in immunology and inflammation.
• The focus on CD19-targeted therapy offers a differentiated approach in the autoimmune disease market.

Risks

• The acquisition is subject to stockholder approval and customary closing conditions, and may not be completed.
• The combined company may not achieve the anticipated benefits of the acquisition.
• The combined company will incur net losses for the foreseeable future and may never achieve or maintain profitability.
• The combined company will need additional funding, which may not be available on acceptable terms, or at all.
• The combined company will rely on third parties to conduct its clinical trials and some aspects of its research and preclinical testing, and those third parties may not perform their obligations satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.
• The combined company may encounter substantial delays in its clinical trials or may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

Future Outlook

The combined company plans to focus on advancing TNT119 for a range of autoimmune-mediated diseases, with Phase 2 clinical trials expected to begin in the second half of 2024, and aims to expand the pipeline through additional indications and business development.

Management Comments

• Andrew Levin stated that the acquisition presents a compelling opportunity for Eliem's stockholders.
• Stephen Thomas expressed excitement about joining Eliem and advancing TNT119 for autoimmune diseases.

Industry Context

The acquisition reflects a trend in the biotechnology industry of companies seeking to expand their pipelines through strategic acquisitions and financings, particularly in the high-growth area of autoimmune disease therapies.

Comparison to Industry Standards

• TNT119 is positioned as a potentially best-in-class anti-CD19 antibody, competing with inebilizumab (UPLIZNA) by Amgen and tafasitamab by Incyte.
• The company aims for a differentiated target product profile compared to existing B-cell targeted therapies like rituximab and belimumab.
• The company is leveraging data from CD19-directed CAR-T studies to inform the development of TNT119, while addressing potential safety and tolerability concerns associated with CAR-T.

Management Changes

Stakeholder Impact

• Shareholders of Eliem and Tenet will be impacted by the ownership structure of the combined company.
• Patients with autoimmune diseases may benefit from the development of TNT119.
• Employees of Eliem and Tenet will be affected by the integration of the two companies.

Next Steps

• Obtain Eliem stockholder approval for the acquisition and private placement.
• Close the acquisition and private placement in mid-2024.
• Initiate Phase 2 clinical trials of TNT119 for SLE and ITP in the second half of 2024.
• Finalize subcutaneous formulation of TNT119 by the end of 2024.
• Present additional data from the MN Phase 1b study by YE 2024.

Key Dates

Keywords

Eliem Therapeutics, Tenet Medicines, Acquisition, Private Placement, TNT119, Autoimmune Diseases, CD19, Systemic Lupus Erythematosus, Immune Thrombocytopenia, Membranous Nephropathy, Clinical Trials, Biotechnology